Literature DB >> 18842680

Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts.

Renato Wirthner1, Simon Wrann, Kuppusamy Balamurugan, Roland H Wenger, Daniel P Stiehl.   

Abstract

A mismatch between metabolic demand and oxygen delivery leads to microenvironmental changes in solid tumors. The resulting tumor hypoxia is associated with malignant progression, therapy resistance and poor prognosis. However, the molecular mechanisms underlying therapy resistance in hypoxic tumors are not fully understood. The hypoxia-inducible factor (HIF) is a master transcriptional activator of oxygen-regulated gene expression. Transformed mouse embryonic fibroblasts (MEFs) derived from HIF-1alpha-deficient mice are a popular model to study HIF function in tumor progression. We previously found increased chemotherapy and irradiation susceptibility in the absence of HIF-1alpha. Here, we show by single-cell electrophoresis, histone 2AX phosphorylation and nuclear foci formation of gammaH2AX and 53BP1, that the number of DNA double-strand breaks (DSB) is increased in untreated and etoposide-treated HIF-deficient MEFs. In etoposide-treated cells, cell cycle control and p53-dependent gene expression were not affected by the absence of HIF-1alpha. Using a candidate gene approach to screen 17 genes involved in DNA repair, messenger RNA (mRNA) and protein of three members of the DNA-dependent protein kinase complex were found to be decreased in HIF-deficient MEFs. Of note, residual HIF-1alpha protein in cancer cells with a partial HIF-1alpha mRNA knockdown was sufficient to confer chemoresistance. In summary, these data establish a novel molecular link between HIF and DNA DSB repair. We suggest that selection of early, non-hypoxic tumor cells expressing low levels of HIF-1alpha might contribute to HIF-dependent tumor therapy resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842680     DOI: 10.1093/carcin/bgn231

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

1.  Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?

Authors:  Glen Kristiansen; Junmin Hu; Daniela Wichmann; Daniel P Stiehl; Michael Rose; Josefine Gerhardt; Annette Bohnert; Anette ten Haaf; Holger Moch; James Raleigh; Mahesh A Varia; Patrick Subarsky; Francesca M Scandurra; Erich Gnaiger; Eva Gleixner; Anne Bicker; Max Gassmann; Thomas Hankeln; Edgar Dahl; Thomas A Gorr
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

Review 2.  Cancer stem cells and drug resistance: the potential of nanomedicine.

Authors:  Serguei Vinogradov; Xin Wei
Journal:  Nanomedicine (Lond)       Date:  2012-04       Impact factor: 5.307

Review 3.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

4.  Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events.

Authors:  Steffi Lehmann; Daniel P Stiehl; Michael Honer; Marco Dominietto; Ruth Keist; Ivana Kotevic; Kristin Wollenick; Simon Ametamey; Roland H Wenger; Markus Rudin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-31       Impact factor: 11.205

5.  Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.

Authors:  Nadine Rohwer; Christof Dame; Anja Haugstetter; Bertram Wiedenmann; Katharina Detjen; Clemens A Schmitt; Thorsten Cramer
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

6.  Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Authors:  Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-07       Impact factor: 9.236

7.  Activation of Hif1α by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity.

Authors:  Marina K Ayrapetov; Chang Xu; Yingli Sun; Kaya Zhu; Kalindi Parmar; Alan D D'Andrea; Brendan D Price
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

8.  Tumor hypoxia as a driving force in genetic instability.

Authors:  Kaisa R Luoto; Ramya Kumareswaran; Robert G Bristow
Journal:  Genome Integr       Date:  2013-10-24

Review 9.  The role of HIF-1α in chemo-/radioresistant tumors.

Authors:  Yu Xia; Lixia Jiang; Tianyu Zhong
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

10.  The Transcription Factor Hif-1 Enhances the Radio-Resistance of Mouse MSCs.

Authors:  Irene Calvo-Asensio; Eugène T Dillon; Noel F Lowndes; Rhodri Ceredig
Journal:  Front Physiol       Date:  2018-04-26       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.